KardioLEV s.r.o.

At KardioLEV s.r.o. researchers are focusing on atherosclerotic cardiovascular disease, testing a novel lipid‑lowering agent to lower the risk of major adverse cardiovascular events (MACE) such as heart attack and stroke.

• Atherosclerotic plaque buildup
• Lipid‑modifying therapy evaluation
• Cardiovascular event reduction

The site in Levoca, Slovakia is conducting four trials with four investigators, all within the cardiovascular therapeutic area.

The centre is conducting studies in atrial fibrillation to improve prevention of stroke and systemic embolism, comparing the new anticoagulant asundexian with standard therapy.

• Stroke prevention
• Bleeding risk comparison
• Anticoagulant efficacy

Based in Levoca, Slovakia, KardioLEV s.r.o. is running four cardiovascular trials with a dedicated team of four investigators.

In patients with heart failure with preserved or mildly reduced ejection fraction and obesity, trials evaluate the drug maridebart cafraglutide to reduce hospitalizations and cardiovascular death.

• Heart failure events
• Weight‑related outcomes
• Cardiovascular mortality

KardioLEV s.r.o., located in Levoca, Slovakia, contributes four clinical studies led by four investigators, all centered on cardiovascular health.